Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 261-268

  An, Hui Mei ^a   Tan, Yun Long ^a   Shi, Jing ^a   Wang, Zhi Ren ^a   Soars, Jair C ^c   Wu, Jing Qin ^d   Yang, Fu De ^a   Huang, Xu Feng ^b   Zhang, Xiang Yang ^a,c  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c University of Texas Harris County Psychiatric Center   (United States)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Immune; Interleukin; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PERPHENAZINE; RISPERIDONE; SULPIRIDE; IL2 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSKINESIA; EDUCATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT DURATION; BLOOD; BLOOD ANALYSIS; CHRONIC DISEASE; COMPLICATION; MIDDLE AGED; MOTOR DYSFUNCTION; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84923226897     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.12.037     Document Type: Article

References (83)

1. Al-Asmari A.K., Khan M.W. Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum. Exp. Toxicol. 2014, 33(2):115-122.
2. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996, 20(1-2):199-203.
3. Bishnoi M., Chopra K., Kulkarni S.K. Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. Eur. J. Pharmacol. 2008, 590(1-3):241-245.
4. Bishnoi M., Chopra K., Kulkarni S.K. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol. Biochem. Behav. 2008, 88(4):511-522.
5. Bocchio Chiavetto L., Boin F., Zanardini R., Popoli M., Michelato A., Bignotti S., Tura G.B., Gennarelli M. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry 2002, 51(6):480-484.
6. Borovcanin M., Jovanovic I., Radosavljevic G., Djukic Dejanovic S., Stefanovic V., Arsenijevic N., Lukic M.L. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr. Res. 2013, 147(1):103-109.
7. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977, 196(4287):326-328.
8. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Mediat. Inflamm. 1993, 2(1):3-21.
9. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry 2000, 61(Suppl. 4):5-9.
10. Chen W.Q., Zhao X.L., Hou Y., Li S.T., Hong Y., Wang D.L., Cheng Y.Y. Protective effects of green tea polyphenols on cognitive impairments induced by psychological stress in rats. Behav. Brain Res. 2009, 202(1):71-76.
11. Chen M.L., Tsai T.C., Wang L.K., Lin Y.Y., Tsai Y.M., Lee M.C., Tsai F.M. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-alpha-directed cell apoptosis in neutrophils. Int. Immunopharmacol. 2012, 12(1):197-204.
12. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatr. 2008, 21(2):151-156.
13. de Araujo E.G., da Silva G.M., Dos Santos A.A. Neuronal cell survival: the role of interleukins. Ann. N. Y. Acad. Sci. 2009, 1153:57-64.
14. De Simoni M.G., Imeri L. Cytokine-neurotransmitter interactions in the brain. Biol. Signals Recept. 1998, 7(1):33-44.
15. de Witte L., Tomasik J., Schwarz E., Guest P.C., Rahmoune H., Kahn R.S., Bahn S. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 2014, 154(1-3):23-29.
16. Dennison U., McKernan D., Cryan J., Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol. Med. 2012, 42(9):1865-1871.
17. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013, 31:90-95.
18. Dunjic-Kostic B., Jasovic-Gasic M., Ivkovic M., Radonjic N.V., Pantovic M., Damjanovic A., Poznanovic S.T., Jovanovic A., Nikolic T., Petronijevic N.D. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr. Danub. 2013, 25(1):55-61.
19. Ebrinc S., Top C., Oncul O., Basoglu C., Cavuslu S., Cetin M. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. J. Int. Med. Res. 2002, 30(3):314-317.
20. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegener. 2009, 4:47.
21. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 1980, 283(5747):569-570.
22. Ganguli R., Brar J.S., Chengappa K.N., Yang Z.W., Nimgaonkar V.L., Rabin B.S. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 1993, 25(5):489-496.
23. Howland R.H. Drug therapies for tardive dyskinesia: part 2. J. Psychosoc. Nurs. Ment. Health Serv. 2011, 49(7):17-20.
24. Kalmady S.V., Venkatasubramanian G., Shivakumar V., Gautham S., Subramaniam A., Jose D.A., Maitra A., Ravi V., Gangadhar B.N. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility?. PLoS One 2014, 9(5):e96021.
25. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000, 44(3):165-175.
26. Klawans H.L., Rubovits R. An experimental model of tardive dyskinesia. J. Neural Transm. 1972, 33(3):235-246.
27. Klemettila J.P., Kampman O., Seppala N., Viikki M., Hamalainen M., Moilanen E., Leinonen E. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res. 2014, 218(3):277-283.
28. Kochunov P., Hong L.E. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. Schizophr. Bull. 2014, 40(4):721-728.
29. Krause D., Weidinger E., Dippel C., Riedel M., Schwarz M.J., Muller N., Myint A.M. Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia. Psychiatr. Danub. 2013, 25(4):389-397.
30. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157(5):683-694.
31. Kulkarni S.K., Naidu P.S. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc) 2003, 39(1):19-49.
32. Kulkarni S.K., Bishnoi M., Chopra K. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. Indian J. Exp. Biol. 2009, 47(2):91-97.
33. Lapchak P.A. A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport 1992, 3(2):165-168.
34. Larouche A., Berube P., Sarret P., Grignon S. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 2008, 62(1):70-73.
35. Liu H., Kang Y., Liang J., Li C., Xiu M., Chen D., Yang F., Wang F., Wu G., Haile C.N., Kosten T.A., Kosten T.R., Zhang X.Y. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012, 198(2):329-331.
36. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS drugs 2003, 17(1):47-62.
37. Maes M., Stevens W., Scharpe S., Bosmans E., De Meyer F., D'Hondt P., Peeters D., Thompson P., Cosyns P., De Clerck L., et al. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia 1994, 50(9):821-829.
38. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29(2):141-152.
39. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Lin A., Racagni G., Altamura C.A. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 2000, 10(2):119-124.
40. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry 2001, 6(4):475-480.
41. Maggiore G., De Benedetti F., Massa M., Pignatti P., Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 1995, 20(1):23-27.
42. Masek K., Slansky J., Petrovicky P., Hadden J.W. Neuroendocrine immune interactions in health and disease. Int. Immunopharmacol. 2003, 3(8):1235-1246.
43. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009, 33(3):355-366.
44. Merrill J.E. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother. 1992, 12(3):167-170.
45. Meyer U., Feldon J., Schedlowski M., Yee B.K. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav. Immun. 2006, 20(4):378-388.
46. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
47. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 1996, 20(3):269-273.
48. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 2008, 160(3):256-262.
49. O'Connell K.E., Thakore J., Dev K.K. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr. Res. 2014, 156(1):1-8.
50. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 1997, 73(1-2):183-190.
51. Petitto J.M., Huang Z., Meola D., Ha G.K., Dauer D. Interleukin-2 and the septohippocampal system: intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders. Methods Mol. Biol. 2012, 829:433-443.
52. Petitto J.M., Meola D., Huang Z. Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models. Methods Mol. Biol. 2012, 934:301-311.
53. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol. Cell Biol. 2001, 79(4):350-357.
54. Pollmacher T., Haack M., Schuld A., Kraus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J. Psychiatr. Res. 2000, 34(6):369-382.
55. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
56. Proost P., Wuyts A., van Damme J. The role of chemokines in inflammation. Int. J. Clin. Lab. Res. 1996, 26(4):211-223.
57. Rankin J.S., Zalcman S.S., Zhu Y., Siegel A. Short- and long-term effects of interleukin-2 treatment on the sensitivity of periadolescent female mice to interleukin-2 and dopamine uptake inhibitor. PloS one 2013, 8(5):e64473.
58. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 1994, 90(5):311-315.
59. Rapaport M.H., McAllister C.G., Kim Y.S., Han J.H., Pickar D., Nelson D.L., Kirch D.G., Paul S.M. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol. Psychiatry 1994, 35(10):767-771.
60. Rapaport M.H., Caligiuri M.P., Lohr J.B. An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1997, 21(5):817-827.
61. Rapaport M.H., McAllister C.G., Pickar D., Tamarkin L., Kirch D.G., Paul S.M. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res. 1997, 25(2):123-129.
62. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., Di Nicola M., Grilli A. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 2011, 12:13.
63. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Curr. Opin. Psychiatry 2007, 20(2):131-137.
64. Ringheim G.E., Burgher K.L., Heroux J.A. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J. Neuroimmunol. 1995, 63(2):113-123.
65. Romagnani P., Annunziato F., Piccinni M.P., Maggi E., Romagnani S. Cytokines and chemokines in T lymphopoiesis and T-cell effector function. Immunol. Today 2000, 21(9):416-418.
66. Sasayama D., Hattori K., Wakabayashi C., Teraishi T., Hori H., Ota M., Yoshida S., Arima K., Higuchi T., Amano N., Kunugi H. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatr. Res. 2013, 47(3):401-406.
67. Sawada M., Itoh Y., Suzumura A., Marunouchi T. Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci. Lett. 1993, 160(2):131-134.
68. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39(4):486-487.
69. Siddiqi A., Monson J.P., Wood D.F., Besser G.M., Burrin J.M. Serum cytokines in thyrotoxicosis. J. Clin. Endocrinol. Metab. 1999, 84(2):435-439.
70. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47(1):1-5.
71. Song C., Merali Z., Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999, 88(3):823-836.
72. Song X., Fan X., Li X., Zhang W., Gao J., Zhao J., Harrington A., Ziedonis D., Lv L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia. Psychopharmacol. (Berl) 2014, 231(2):319-325.
73. Tarsy D., Baldessarini R.J. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 1974, 13(10-11):927-940.
74. Thaakur S., Himabindhu G. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. J. Neural Transm. 2009, 116(7):807-814.
75. Tourjman V., Kouassi E., Koue M.E., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151(1-3):43-47.
76. Trevizol F., Benvegnu D.M., Barcelos R.C., Pase C.S., Segat H.J., Dias V.T., Dolci G.S., Boufleur N., Reckziegel P., Burger M.E. Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. Behav. Brain Res. 2011, 221(1):13-18.
77. Upthegrove R., Manzanares-Teson N., Barnes N.M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 2014, 155(1-3):101-108.
78. van Kammen D.P., McAllister-Sistilli C.G., Kelley M.E., Gurklis J.A., Yao J.K. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1999, 87(2-3):129-136.
79. Zalcman S.S. Interleukin-2-induced increases in climbing behavior: inhibition by dopamine D-1 and D-2 receptor antagonists. Brain Res. 2002, 944(1-2):157-164.
80. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994, 643(1-2):40-49.
81. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002, 57(2-3):247-258.
82. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65(7):940-947.
83. Zhang X.Y., Zhou D.F., Qi L.Y., Chen S., Cao L.Y., Chen da C., Xiu M.H., Wang F., Wu G.Y., Lu L., Kosten T.A., Kosten T.R. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology 2009, 204(1):177-184.